Effect of DNMT SNPs on DNA Methylation in Primary ITP
NCT04100876 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90
Last updated 2019-09-24
Summary
* To compare global DNA methylation status between ITP patients and healthy subjects .
* To determine the effect of DNMT3A -448 G/A SNP variant A allele and DNMT3B -149C/T SNP variant T-allele on global DNA methylation in both ITP patients and healthy control subjects.
Conditions
- Primary Immune Thrombocytopenia
Interventions
- GENETIC
-
Global DNA methylation will be quantified in the DNA samples by colorimetry
Global DNA methylation will be quantified in the DNA samples by colorimetry
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Heba A Abdel-Hafeez, Professor · Clinical Pathology Department in Assuit University Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-12-01
- Primary Completion
- 2021-10-01
- Completion
- 2021-12-01
More Related Trials
-
The Study of Different Dose Rituximab in the Treatment of ITP
NCT03258866 ·Status: COMPLETED ·Phase: PHASE4
-
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
NCT04518475 ·Status: RECRUITING ·Phase: PHASE4
-
Alteration of Different Immune Parameters in Immune Thrombocytopenia (ITP) Patients Receiving Eltrombopag Treatment
NCT01864512 ·Status: WITHDRAWN
-
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
NCT01719692 ·Status: COMPLETED ·Phase: NA
-
Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
NCT05116423 ·Status: UNKNOWN
-
Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)
NCT04949009 ·Status: UNKNOWN
-
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
NCT05333861 ·Status: NOT_YET_RECRUITING
-
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00454857 ·Status: COMPLETED
-
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
NCT01762761 ·Status: COMPLETED ·Phase: PHASE3
-
TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years
NCT04890041 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
NCT05311930 ·Status: UNKNOWN ·Phase: PHASE4
-
High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial
NCT05943691 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP
NCT05846529 ·Status: UNKNOWN
-
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
NCT06838949 ·Status: RECRUITING ·Phase: PHASE2
-
Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
NCT01196884 ·Status: UNKNOWN
-
A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy
NCT02391272 ·Status: COMPLETED ·Phase: PHASE3
-
Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)
NCT03469661 ·Status: COMPLETED
-
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
NCT06531018 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
NCT03443570 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
NCT06658834 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)
NCT04089267 ·Status: COMPLETED ·Phase: PHASE4
-
ITP Registry and Accompanying Biospecimen Collection
NCT05152238 ·Status: RECRUITING
-
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
NCT00005570 ·Status: COMPLETED
-
Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
NCT06665308 ·Status: COMPLETED
-
Phase III Study on HMPL-523 for Treatment of ITP
NCT05029635 ·Status: COMPLETED ·Phase: PHASE3